
Tricida TCDA
Quarterly report 2022-Q3
added 11-14-2022
Tricida Accounts Payables 2011-2025 | TCDA
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 M | 3.51 M | 5.91 M | 8.46 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10 M | 3.51 M | 6.98 M |
Quarterly Accounts Payables Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 4.4 M | 3.74 M | 5.54 M | 10 M | 3.26 M | 2.74 M | 5.32 M | 3.51 M | 3.51 M | 3.51 M | 3.51 M | 5.91 M | 5.91 M | 5.91 M | 5.91 M | 8.46 M | 8.46 M | 8.46 M | 8.46 M | 3.86 M | 3.86 M | 3.86 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10 M | 2.74 M | 5.37 M |
Accounts Payables of other stocks in the Drug manufacturers industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
8.25 M | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
8.28 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
26.1 M | $ 1.24 | -5.73 % | $ 133 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
670 K | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
7.94 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
9.57 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
361 M | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
1.78 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
19 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
94.7 M | - | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
112 M | $ 12.28 | -3.0 % | $ 629 M | ||
|
Athenex
ATNX
|
33.7 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
7.33 M | $ 21.59 | 0.02 % | $ 2.05 B | ||
|
Evolus
EOLS
|
9.24 M | $ 6.79 | -0.95 % | $ 421 M | ||
|
Harrow Health
HROW
|
27.3 M | $ 50.31 | 0.3 % | $ 1.64 B | ||
|
China Pharma Holdings
CPHI
|
225 K | $ 1.18 | -9.92 % | $ 20.6 M | ||
|
Organogenesis Holdings
ORGO
|
28.9 M | $ 5.37 | -8.6 % | $ 707 M | ||
|
Bausch Health Companies
BHC
|
719 M | $ 7.17 | -0.35 % | $ 2.62 B | ||
|
Pacira BioSciences
PCRX
|
19.1 M | $ 26.42 | 1.54 % | $ 1.22 B | ||
|
Lannett Company
LCI
|
29.7 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
2.6 M | - | - | $ 193 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
13.9 M | $ 4.16 | -0.95 % | $ 58.5 M | ||
|
Rockwell Medical
RMTI
|
4.52 M | $ 0.82 | 0.95 % | $ 19.1 M | ||
|
Solid Biosciences
SLDB
|
4.24 M | $ 5.9 | - | $ 241 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
953 K | $ 3.53 | -3.16 % | $ 4.38 M | ||
|
PetIQ
PETQ
|
139 M | - | 1.64 % | $ 400 M | ||
|
Radius Health
RDUS
|
17.6 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
1.31 M | - | -4.76 % | $ 65.3 M | ||
|
Jupiter Wellness
JUPW
|
2.22 M | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
495 M | $ 13.78 | 0.29 % | $ 1.89 B | ||
|
ProPhase Labs
PRPH
|
5.9 M | $ 0.52 | -15.2 % | $ 8.24 M | ||
|
Relmada Therapeutics
RLMD
|
3.51 M | $ 4.47 | -2.88 % | $ 135 M | ||
|
Veru
VERU
|
3.04 M | $ 2.3 | -1.71 % | $ 310 M | ||
|
cbdMD
YCBD
|
1.54 M | $ 1.67 | 2.45 % | $ 7.2 M | ||
|
OptiNose
OPTN
|
3.89 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
13.4 M | $ 9.68 | -2.21 % | $ 688 M | ||
|
SCYNEXIS
SCYX
|
7.15 M | $ 0.58 | -2.39 % | $ 27.8 M | ||
|
Tilray
TLRY
|
70.8 M | $ 9.71 | -4.34 % | $ 6 B | ||
|
TherapeuticsMD
TXMD
|
27 K | $ 1.7 | - | $ 17.7 M | ||
|
Viatris
VTRS
|
1.77 B | $ 12.33 | 0.71 % | $ 14.9 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
1.94 M | - | - | $ 55.5 M |